Logo

SOPH

SOPHiA GENETICS S.A.

SOPH

SOPHiA GENETICS S.A. • NASDAQ
$4.92 ▼ -0.20% (-0.01)
Market Cap $330.24 M
52w High $5.30
52w Low $2.58
Dividend Yield 0%
P/E -4.39
Volume 56.82K
Outstanding Shares 67.12M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $19.462M ▲ $30.769M ▼ $-20.021M ▲ -102.872% ▲ $-0.3 ▲ $-17.243M ▲
Q2-2025 $18.323M ▲ $30.828M ▲ $-22.414M ▼ -122.327% ▼ $-0.33 ▼ $-18.723M ▼
Q1-2025 $17.779M ▲ $28.244M ▼ $-17.385M ▼ -97.784% ▼ $-0.26 ▼ $-13.926M ▼
Q4-2024 $17.733M ▲ $29.546M ▲ $-15.158M ▲ -85.479% ▲ $-0.23 ▲ $-7.946M ▲
Q3-2024 $15.853M $26.017M $-18.438M -116.306% $-0.28 $-13.15M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $81.61M ▼ $163.458M ▼ $102.771M ▲ $60.687M ▼
Q2-2025 $94.822M ▲ $177.62M ▲ $100.928M ▲ $76.692M ▼
Q1-2025 $68.528M ▼ $146.719M ▼ $61.106M ▲ $85.613M ▼
Q4-2024 $80.226M ▼ $155.309M ▼ $58.819M ▼ $96.49M ▼
Q3-2024 $95.787M $177.608M $64.101M $113.507M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-20.021M ▲ $-8.793M ▼ $-2.576M ▼ $-1.987M ▼ $-13.212M ▼ $-8.899M ▲
Q2-2025 $-21.652M ▼ $-8.214M ▲ $-1.552M ▼ $33.539M ▲ $26.294M ▲ $-10.19M ▲
Q1-2025 $-16.882M ▼ $-10.75M ▼ $-1.039M ▲ $-990K ▼ $-11.698M ▲ $-12.241M ▲
Q4-2024 $-14.542M ▲ $-10.601M ▼ $-1.94M ▲ $-573K ▼ $-15.561M ▼ $-12.541M ▼
Q3-2024 $-18.308M $-7.159M $-4.116M $-21K $-9.609M $-9.48M

Five-Year Company Overview

Income Statement

Income Statement Revenue has climbed steadily each year, showing that demand for the company’s data‑driven medicine platform is growing. Gross profit is positive and relatively healthy, which suggests the core services are priced well and add real value. The challenge is that operating costs, especially for R&D, sales, and overhead, are still much higher than gross profit, so the company remains meaningfully loss‑making. Losses peaked a couple of years ago and have started to narrow, but the business is still far from break‑even and depends on continued growth and cost discipline to improve its earnings profile.

Balance Sheet

Balance Sheet The balance sheet is asset‑light and largely driven by cash and technology assets rather than hard equipment. Cash and total assets swelled around the IPO and have been gradually drawn down since, reflecting ongoing losses and investment in the platform. Debt remains relatively modest compared with equity, so leverage risk looks limited for now. However, shareholders’ equity has been eroded as losses accumulate, and the financial cushion is shrinking over time, which reduces flexibility if growth or fundraising conditions weaken.

Cash Flow

Cash Flow The company consistently spends more cash than it brings in from operations, which means it is still in investment and build‑out mode rather than self‑funding. Operating cash outflows have been sizable but appear to be slowly improving, suggesting some early benefits from scale and cost control. Capital spending is relatively low and stable, so most of the cash burn comes from funding people, R&D, and commercial expansion, not from heavy equipment. If current trends continue, the business will likely need either stronger revenue growth or additional external capital over time to sustain its innovation pace and global expansion.

Competitive Edge

Competitive Edge SOPHiA GENETICS operates in a fast‑growing niche at the intersection of genomics, AI, and cloud software, where strong data and algorithms can create real differentiation. Its SOPHiA DDM platform benefits from a large and expanding network of hospitals and labs, which improves the AI models as more cases are processed and creates a data advantage that is hard for new entrants to copy. The federated learning approach addresses sensitive data‑privacy concerns and can make adoption easier for institutions that want advanced analytics without giving up control of their data. High switching costs and a “land‑and‑expand” strategy support customer stickiness, but the company still faces intense competition from other genomic, diagnostic, and healthcare AI platforms, along with reimbursement and regulatory complexity that can slow adoption.

Innovation and R&D

Innovation and R&D The business is built around heavy investment in advanced AI for genomics and multimodal data, and that R&D focus is clearly a strategic priority. Its platform handles not just genetic data but also imaging and clinical information, and newer concepts like digital twins, HRD analysis, and liquid biopsy tools highlight a push to stay at the leading edge of precision oncology. Collaborations, such as those with major cancer centers and a multi‑year partnership with a large biopharma company, validate the technology and open doors to new revenue streams in drug development and clinical trials. At the same time, this innovation engine is expensive, and the payoff depends on how quickly healthcare systems adopt these tools, how well the company can turn pilots into scaled deployments, and how it keeps pace with rapid advances from both established players and startups.

Summary

Overall, SOPHiA GENETICS looks like a classic high‑innovation, early‑stage healthcare technology company: growing revenue, strong technology differentiation, and deep R&D, but still meaningfully unprofitable with ongoing cash burn. Its strengths lie in its AI‑driven platform, rich data network, and sticky customer relationships, which together create a promising foundation in precision medicine and biopharma services. The key risks center on execution: scaling revenue fast enough, managing costs and cash, navigating competition, and proving that new offerings such as digital twins and advanced oncology applications can be commercially adopted at scale. How well the company balances its ambition in innovation with progress toward financial self‑sufficiency will be the main factor shaping its long‑term trajectory.

NEWS

November 11, 2025 · 9:00 AM UTC

SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine

Read more

November 11, 2025 · 8:01 AM UTC

SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine

Read more

November 4, 2025 · 6:45 AM UTC

SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance

Read more

October 21, 2025 · 8:00 AM UTC

SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025

Read more

October 16, 2025 · 11:00 AM UTC

A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan

Read more